Radar · Oncology in Cambridge
Best Oncology Companies in Cambridge, United Kingdom
The 49 best Oncology companies in Cambridge, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Apollo Therapeutics.
By Riya SenguptaFinancials
49companies tracked
$2.3Bdisclosed funding
0unicorns
39have raised
FLIAR INTELLIGENCE · ONCOLOGY × CAMBRIDGE
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
184kcombined LinkedIn audience
50%of audience held by top 3
2companies hiring publicly (12 mo)
Ranked: Best Oncology companies in Cambridge
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Apollo Therapeutics Developer of therapeutic programs based on biological and medical research | $372M | 35 mo ago | 11 | Richard Mason CEO | Series C | — | — | — |
| 2 | Kymab Provider of monoclonal antibody therapeutics for multiple diseases | $348M | 85 mo ago | 183 | Allan Bradley Founder & Director | Acquired | — | 872 patents Immunotherapy antibodies targeting immune checkpoints and co‑stimulatory receptors | — |
| 3 | Artios Developer of therapeutics targeting the deoxyribonucleic acid damage response in cancer 45Funding top 24%Talent top 28%Moat top 31%Tech top 49% All 8 signals ▾Fundingtop 24% Talenttop 28% Moattop 31% Techtop 49% Markettop 50% Growthbottom 46% Globalbottom 39% Fin. healthbottom 32% Funding: Raised $273M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) Talent: 4 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $273M | 8 mo ago | 76 | Shweta Nair Founder | Series D | WordPressMySQLPHP+15 | — | — |
| 4 | Inivata Developer of liquid biopsy platform for detecting cancer | $189M | 66 mo ago | 81 | Davina Gale Co-founder | Acquired | — | 97 patents Liquid biopsy and nucleic‑acid analysis for cancer detection and monitoring. | — |
| 5 | Crescendo Biotechnology company developing antibody-based cancer immunotherapies and targeted biologic treatments | $141M | 36 mo ago | 43 | Theodora Harold CEO | Series B | — | — | — |
| 6 | Healx Provider of AI-powered drug discovery solutions for rare diseases 64Innovation top 25%AI top 26%Moat top 26%Patents top 27% All 12 signals ▾Innovationtop 25% AItop 26% Moattop 26% Patentstop 27% Fundingtop 29% Talenttop 38% Growthtop 42% Techtop 48% Globalbottom 47% Marketbottom 46% Fin. healthbottom 28% Newsbottom 18% Innovation: 105 patents (top 10% of patent-holders) · 57 filings since 2022 vs 48 in 2017-21 AI: Classified as an AI company · Product described with: ai-powered, machine learning rank vs industry peers · Fliar Intelligence Index 64/100 | $115M | 24 mo ago | 80 80 → 69 (-14%) | David Brown Co-Founder | Series C | WordPressMySQLPHP+22 | 105 patents Drug repurposing of existing compounds for rare cancers and polycystic kidney disease | — |
| 7 | CellCentric Developer of oral small molecule inhibitors for treating blood cancers 50Funding top 21%Talent top 32%News top 33%Growth top 35% All 11 signals ▾Fundingtop 21% Talenttop 32% Newstop 33% Growthtop 35% Patentstop 39% Moattop 43% Partnersbottom 49% Innovationbottom 48% Techbottom 45% Globalbottom 44% Marketbottom 35% Funding: Raised $90.3M across 8 rounds · 8 rounds over 23 yrs (0.3/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $90M | 3 mo ago | 18 | Azim Surani Co-Founder | Series D | WordPressMySQLPHP+20 | 86 patents Synthesis of small‑molecule p300/CBP epigenetic modulators for therapeutic use | 1 launch |
| 8 | Bicycle Developer of synthetic peptide molecules for targeted solid tumor treatment | $90M | 26 mo ago | 40 | Greg Winter Co-Founder & Director | Public | WordPressMySQLPHP+17 | 17 patents Design of bicyclic peptide therapeutics and conjugated oligonucleotide drug candidates | — |
| 9 | Amphista Therapeutics Developer of targeted protein degradation medicines for treating pathogenic proteins | $60M | 43 mo ago | 12 | Louise Modis Chief Executive Officer | Series B | WordPressPleskMySQL+26 | 38 patents Small-molecule PROTACs for targeted protein degradation | — |
| 10 | Biofidelity Developer of a molecular diagnostic assay for the detection of target DNA sequences | $60M | 28 mo ago | 12 12 → 29 (+142%) | Barney Balmforth Co-Founder & CEO | Series B | — | 70 patents Sensitive nucleic acid and epigenetic marker detection/enrichment technologies | — |
| 11 | T-Therapeutics Developer of T-cell-based rtherapeutics for cancer treatment 62Patents top 12%Innovation top 19%Moat top 26%News top 27% All 10 signals ▾Patentstop 12% Innovationtop 19% Moattop 26% Newstop 27% Fundingtop 30% Growthtop 32% Talenttop 38% Techbottom 47% Globalbottom 45% Marketbottom 32% Patents: 239 patents matched (strict assignee match) · 105 filings since 2022 vs 14 in 2017-21 Innovation: 239 patents (top 11% of patent-holders) · 105 filings since 2022 vs 14 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $59M | 8 mo ago | — | Haydn Prosser Co-Founder & Director | Series A | WordPressMySQLPHP+21 | 232 patents RNA/oligonucleotide therapeutics targeting gene expression inhibition and splice modulation | 1 job opening |
| 12 | KuDos Pharmaceuticals Developer of oncology therapies based on the inhibition of DNA repair | $54M | 82 mo ago | 8,185 | Barrie ward Ex-CEO | Acquired | — | — | — |
| 13 | Azeria Therapeutics Developer of therapies for treating hormone-resistant breast and prostate cancer | $48M | 80 mo ago | 11 | Jason Carroll Founder | Series B | — | — | — |
| 14 | Mestag Therapeutics Developer of therapeutics for the treatment of cancer and inflammatory diseases 35Talent top 23%Funding top 28%Moat top 39%Tech bottom 46% All 6 signals ▾Talenttop 23% Fundingtop 28% Moattop 39% Techbottom 46% Globalbottom 37% Marketbottom 26% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated Funding: Raised $45.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $45M | 4 mo ago | 8 | David Tuveson Co-Founder | Series A | WordPressMySQLPHP+17 | — | — |
| 15 | Epitopea Developer of immunotherapeutics for the treatment of cancer | $45M | 21 mo ago | 10 | Jon Moore CEO | Seed | WordPressPleskMySQL+17 | — | — |
| 16 | NeoPhore Developer of small molecule therapies to treat cancer | $45M | 30 mo ago | 10 10 → 18 (+80%) | Alberto Bardelli Co-Founder | Series B | ZURB FoundationApache HTTP ServerTypekit+7 | 32 patents Patents concentrated in chemistry & materials | — |
| 17 | Endomag Developer of a device and platform for tumor localization | $45M | 68 mo ago | 112 | Simon Hattersley Co-Founder | Acquired | PrismicApple iCloud MailMicrosoft 365+19 | — | — |
| 18 | Acacia Pharma Developer of therapeutic solutions for treating cancer | $34M | 65 mo ago | 74 | Gabriel Fox Chief Medical Officer | Acquired | — | 192 patents Pharmaceutical anti-emetic formulations, especially amisulpride-based treatments for postoperative nausea | — |
| 19 | Cycle Pharma Small molecule drug reformulation and repurposing for orphan indications | $25M | 71 mo ago | 54 | — | Funding Raised | WordPressMySQLPHP+21 | — | 1 launch |
| 20 | F-star Developer of bispecific antibodies to improve the treatment of cancer | $23M | 184 mo ago | 80 | — | Acquired | WordPressMySQLPHP+18 | 6 patents Interactive educational devices and methods for teaching and learning | — |
| 21 | 14M Genomics Provider of a technology that utilizes next gen sequencing and proprietary analytics for cancer diagnostics | $20M | 139 mo ago | 20 | — | Deadpooled | — | — | — |
| 22 | Xap Therapeutics Developer of cell therapies to treat cancer and autoimmune diseases | $17M | 53 mo ago | 12 | Shaun Foy Co-Founder | Seed | — | — | — |
| 23 | Biosceptre Develops immunotherapies for oncology | $16M | 103 mo ago | 10 10 → 15 (+50%) | — | Early Stage | — | 28 patents Engineering chimeric antigen receptors and cytotoxic particle therapeutics for targeted immunotherapy | — |
| 24 | Lucida Medical Developer of MRI-based cancer screening technology using artificial intelligence (AI) 35Talent top 38%Funding top 44%AI top 45%Moat top 48% All 7 signals ▾Talenttop 38% Fundingtop 44% AItop 45% Moattop 48% Techbottom 48% Globalbottom 37% Marketbottom 27% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $11.5M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $12M | 4 mo ago | 12 12 → 29 (+142%) | Evis Sala Co-Founder | Series A | WordPressMySQLPHP+21 | — | — |
| 25 | Sareum Developer of small molecule therapeutics for cancer and autoimmune diseases | $11M | 36 mo ago | 6 | — | Public | WordPressMySQLPHP+17 | 92 patents Small-molecule TYK2 kinase inhibitors for treating inflammatory and autoimmune diseases | — |
| 26 | Avvinity Therapeutics Developer of immunotherapeutics for immuno-oncology diseases | $8M | 125 mo ago | 5 | — | Deadpooled | — | 15 patents Novel heterocyclic small‑molecule drugs for therapeutic applications | — |
| 27 | Cyted Leader in non-endoscopic diagnostics for digestive health, enabling early disease detection and access to… 53Talent top 28%Funding top 33%Patents top 33%Growth top 35% All 9 signals ▾Talenttop 28% Fundingtop 33% Patentstop 33% Growthtop 35% Innovationtop 37% Moattop 46% Techbottom 45% Globalbottom 40% Marketbottom 32% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $6.6M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $7M | 11 mo ago | — | Maria Odonovan Co-Founder & CMO | Series B | WebflowSalesforceGSAP+15 | 16 patents Endoscopic devices for esophageal cell collection and Barrett's diagnosis | — |
| 28 | Ablatus Therapeutics Developer of a device for bimodal electric tissue ablation | $6M | 29 mo ago | 3 | David Brooks Founder & CEO | Deadpooled | — | — | — |
| 29 | PolyProx Therapeutics Developer of drugs for treatment of cancer | $6M | 77 mo ago | 9 | Albert Perez Riba Co-Founder | Deadpooled | — | — | — |
| 30 | Cambridge Cancer Genomics Developer of AI-based precision medicine tools for oncologists | $5M | 91 mo ago | 16 | — | Acqui-Hired | — | — | — |
| 31 | Sentinel Oncology Drug discovery company developing small molecule therapies for cancer | $4M | 132 mo ago | 5 | — | Funding Raised | Cart FunctionalitySquarespace CommerceSquarespace+12 | 147 patents Small-molecule kinase inhibitors targeting PLK1, CHK1, P70S6K, and WEE1 in oncology | — |
| 32 | Semarion Provider of a platform for drug discovery and screening | $3M | 4 mo ago | 3 | Jeroen Verheyen Co-Founder & CEO | Series A | WordPressMySQLPHP+13 | 4 patents Carrier materials for biocatalytic assays and nucleic‑acid based diagnostics | — |
| 33 | Nuformix Developer of drugs for the treatment of fibrosis and oncology | $2M | 39 mo ago | 4 | Stephen Cash Co-Founder | Public | — | 48 patents Pharmaceutical cocrystal and salt forms of active drug molecules | — |
| 34 | 52 North Health Developer of diagnostic and digital solutions for emergency care settings | $1M | 20 mo ago | 10 | Umaima Malik Ahmad CEO & Co-Founder | Series A | StatamicPHPLaravel+9 | — | — |
| 35 | Tailor Bio Developer of targeted therapies for cancers with chromosomal instability | $772K | 49 mo ago | 10 | Geoff Macintyre Founder | Funding Raised | — | — | — |
| 36 | TexRAD Medical image analysis software for cancer risk assessment, prognosis & diagnosis | $389K | 116 mo ago | 40 | — | Seed | — | 6 patents Medical image texture analysis for diagnostic radiology | — |
| 37 | Alevin Therapeutics Developer of targeted integrin therapies for multiple diseases | — | 48 mo ago | 4 | Chris Moody Founder | Seed | — | — | — |
Top 12 Oncology companies in Cambridge
#1
Series D · Cambridge, England · founded 2003 · 18 employees$90.3Mraised▾
Series D · Cambridge, England · founded 2003 · 18 employees
Developer of oral small molecule inhibitors for treating blood cancers. This pharmaceutical entity focuses on creating therapeutic agents that target specific proteins involved in tumor progression. The research involves modulating gene expression by disrupting the interaction of transcription co-activation factors within cancer cells. The primary therapeutic candidate is designed to address multiple myeloma and other hematological malignancies by binding to bromodomains. This approach aims to reduce the production of proteins that drive tumor growth. The development process includes clinical evaluation to assess safety and efficacy across various patient populations.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 21%Talent
top 32%News
top 33%Growth
top 35%Patents
top 39%Moat
top 43%Funding: Raised $90.3M across 8 rounds · 8 rounds over 23 yrs (0.3/yr) · Last round Series D (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated · 4 leadership moves in 12 mo
News: 6 BI events in 12 mo (of 18 tracked, 6 types) · +50% YoY · 1 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 7k LinkedIn followers — 3.6% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- May 2026Series D$220M
- May 2025Series C$120M
- Jul 2024Series C$35M
- Jul 2023Series C$25M
Founders & team
Investors
Takeda Ventures, Morningside, Nesta Impact Investments, Providence Investment Company, UK Innovation Science & Seed Fund, RA Capital Management
Tech stack
CloudflareCloudflare Browser InsightsCookieyesCore-JsDocusignElementor
#2
Series D · Cambridge, England · founded 2016 · 76 employees$273Mraised▾
Series D · Cambridge, England · founded 2016 · 76 employees
Developer of therapeutics targeting the deoxyribonucleic acid damage response in cancer. These treatments focus on inhibiting specific enzymes involved in cellular repair mechanisms to induce damage within malignant tissues. The approach utilizes small-molecule inhibitors to disrupt survival pathways in tumor cells. Research efforts concentrate on identifying biological targets that regulate replication stress and genomic stability. These therapeutic candidates are evaluated for use as monotherapies or in combination with other agents to address solid tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 24%Talent
top 28%Moat
top 31%Tech
top 49%Market
top 50%Growth
bottom 46%Funding: Raised $273M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Series D (Nov 2025)
Talent: 4 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Nov 2025Series D$115M
- Jul 2021Series C$153M
- Aug 2018Series B$84M
- Sep 2016Series A$36M
Founders & team
Investors
Andera Partners, Life Sciences Partners, Novartis, Arix Bioscience, SV Health Investors, IP Group
Tech stack
BootstrapCloudflareCloudflare Bot ManagementCookie InformationFont AwesomeGodaddy
#3
Series A · Cambridge, England · founded 2020 · 8 employees$45Mraised▾
Series A · Cambridge, England · founded 2020 · 8 employees
Developer of therapeutics for the treatment of cancer and inflammatory diseases. The company has developed therapeutics that interrupt pathological fibroblast-driven immune signaling and influence innate and adaptive immune responses.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 23%Funding
top 28%Moat
top 39%Tech
bottom 46%Global
bottom 37%Market
bottom 26%Talent: 6 named leaders on record · 6 C-suite/founder profiles curated
Funding: Raised $45.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Mar 2026)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 8k LinkedIn followers — 4.2% of this cohort's audience
Funding rounds
- Mar 2026Series A$40M
- Aug 2024Grant (prize money)$2M
- Aug 2021Seed$34M
- Apr 2021Seed$11M
Founders & team
Investors
Forbion, Google Ventures, SV Health Investors, Johnson & Johnson Innovation, Northpond Ventures, Ukri
#4
Series A · Cambridge, England · founded 2022$59.4Mraised▾
Series A · Cambridge, England · founded 2022
Developer of T-cell-based rtherapeutics for cancer treatment. It offers T-cell receptor-based drugs that recognise specific cancers and patient’s own T cells to kill the cancer cells and eradicate the tumour.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 12%Innovation
top 19%Moat
top 26%News
top 27%Funding
top 30%Growth
top 32%Patents: 239 patents matched (strict assignee match) · 105 filings since 2022 vs 14 in 2017-21 · Latest publication 2026
Innovation: 239 patents (top 11% of patent-holders) · 105 filings since 2022 vs 14 in 2017-21
Moat: Editorial + unicorn rating 8/10 · IP moat: 239 patents · Soonicorn
Audience (LinkedIn): 7k LinkedIn followers — 4.0% of this cohort's audience
Hiring (LinkedIn): 4 hiring posts in 12 mo (public) · momentum -2 · hiring: Senior Scientist - Analytical Development, Protein Sciences, Research Associate - Protein Sciences
Funding rounds
- Nov 2025Series A$32M
- Nov 2023Series A$59.4M
Founders & team
Investors
Sanofi Ventures, University of Cambridge, Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital
Tech stack
Animate.CssAnime.JsExactmetricsFancyboxGodaddyGoogle Analytics
#5
Series A · Cambridge, England · founded 2019 · 12 employees$11.5Mraised▾
Series A · Cambridge, England · founded 2019 · 12 employees
Lucida Medical develops MRI-based cancer screening technology using artificial intelligence (AI). The old name of the company was Cambridge AI Health. The company aims to develop novel algorithms for biomedical discovery, omics analytics, early diagnostics, and clinical trials.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Talent
top 38%Funding
top 44%AI
top 45%Moat
top 48%Tech
bottom 48%Global
bottom 37%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Funding: Raised $11.5M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) · Last round Series A (Mar 2026)
AI: Product described with: artificial intelligence
Audience (LinkedIn): 4k LinkedIn followers — 2.4% of this cohort's audience
Funding rounds
- Mar 2026Series A$11.5M
- Mar 2021Seed—
Founders & team
Investors
XTX Markets, IW Capital, Macmillan Cancer Support, Sahsen Ventures, University of Cambridge, The FSE Group
Tech stack
CloudflareCloudflare Bot ManagementContact Form 7DiviExactmetricsGoogle Analytics
#6
Series A · Cambridge, England · founded 2018 · 3 employees$2.9Mraised▾
Series A · Cambridge, England · founded 2018 · 3 employees
Provider of a platform for drug discovery and screening. The company focuses on drug screening and lead identification of GPCR-targeting oncology drugs. The company has developed the proprietary technology called SemaCyte which is the microchip technology and nanomagnetism that helps in drug discovery. It focuses on drug discovery which will target the cell surface receptors such as GPCRs and tyrosine kinases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Mar 2026Series A$3.8M
- Feb 2022Seed$2.9M
Founders & team
Investors
Cambridge Enterprise, Parkwalk, Martlet Capital, The FSE Group, University of Cambridge, Oxford Innovation
#7
Series B · Cambridge, England · founded 2018$6.6Mraised▾
Series B · Cambridge, England · founded 2018
Cyted Health is a gastrointestinal health company pioneering non-endoscopic diagnostics to detect diseases early and provide access to care for everyone. Their technologies aim to revolutionize diagnostics and improve patient care.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Talent
top 28%Funding
top 33%Patents
top 33%Growth
top 35%Innovation
top 37%Moat
top 46%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $6.6M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) · Last round Series B (Sep 2025)
Patents: 16 patents matched (strict assignee match) · 16 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 6k LinkedIn followers — 3.4% of this cohort's audience
Funding rounds
- Sep 2025Series B$43.8M
- Dec 2020Series A$2.9M
- Oct 2020Series A$817.1K
- Aug 2020Series A$2M
Founders & team
Investors
EQT, Advent Life Sciences, British Business Bank, Morningside, BGF
Tech stack
CdnjsCloudflareGoogle AnalyticsGoogle Tag ManagerGoogle WorkspaceGsap
#8
Seed · Cambridge, England · founded 2021 · 10 employees$44.6Mraised▾
Seed · Cambridge, England · founded 2021 · 10 employees
Developer of immunotherapeutics for the treatment of cancer. The company's proprietary technology provides an approach to identify tumor-specific antigens, known as Cryptigens to create transformational immunotherapies including therapeutic vaccines, cell therapies, and TCR-based biologics that target broad cancer patient populations in both solid and hematological cancers.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers — 2.6% of this cohort's audience
Funding rounds
- Oct 2024Seed$31M
- Sep 2024Grant (prize money)$658K
- Apr 2022Seed$13.6M
Founders & team
Investors
Invest Quebec, adMare BioInnovations, Advent Life Sciences, CTI Life Sciences Fund, Cambridge Innovation Capital, Fonds de solidarite FTQ
Tech stack
CivicthemeGoogle AnalyticsGoogle Font ApiHstsIsotopeJquery
#9
Series C · Cambridge, England · founded 2014 · 80 employees$115.4Mraised▾
Series C · Cambridge, England · founded 2014 · 80 employees
Provider of AI-powered drug discovery solutions for rare diseases. It helps identify new drug candidates, repurpose existing compounds, and accelerate rare disease research and development. The company combines machine learning, biomedical knowledge graphs, and expert drug discovery workflows to improve the speed and success rate of bringing treatments to patients.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Innovation
top 25%AI
top 26%Moat
top 26%Patents
top 27%Funding
top 29%Talent
top 38%Innovation: 105 patents (top 10% of patent-holders) · 57 filings since 2022 vs 48 in 2017-21 · Deep-tech classification: Artificial Intelligence
AI: Classified as an AI company · Product described with: ai-powered, machine learning
Moat: Editorial + unicorn rating 8/10 · IP moat: 105 patents · Soonicorn
Audience (LinkedIn): 22k LinkedIn followers — 12.1% of this cohort's audience
Funding rounds
- Aug 2024Series C$47M
- 2022Series C—
- Oct 2019Series B$56M
- Jul 2018Series A$10M
Founders & team
Investors
Atomico, R42 Group, Balderton Capital, BtoV, Global Brain, o2h ventures
Tech stack
Amazon Web ServicesBootstrapCdnjsCloudflareCloudflare Bot ManagementContact Form 7
#10
Series C · Cambridge, England · founded 2020 · 11 employees$371.5Mraised▾
Series C · Cambridge, England · founded 2020 · 11 employees
Developer of therapeutic programs based on biological and medical research. The company's product pipeline include APL-9796: A first-in-class anti-ZIP12 monoclonal antibody for pulmonary hypertension, APL-045 and APL-10456, targeting neoplasms, immune disorders, and metabolic conditions via small molecules and antibodies.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 10k LinkedIn followers — 5.4% of this cohort's audience
Funding rounds
- Sep 2023Series C$226.5M
- Jun 2021Series C$145M
Founders & team
Investors
Patient Square Capital, M&G, Rock Springs Capital, Reimagined Ventures, UCL Technology Fund
#11
Public · Cambridge, England · founded 2009 · 40 employees$89.6Mraised▾
Public · Cambridge, England · founded 2009 · 40 employees
Developer of synthetic peptide molecules for targeted solid tumor treatment. These molecules utilize constrained structural geometry to facilitate binding with affinity and selectivity. The technology focuses on penetrating deep into tissues to address specific antigens. Research efforts include the creation of toxin conjugates, immune cell agonists, and imaging agents for diagnostic and therapeutic applications. The development pipeline targets various cancers and other medical conditions requiring modulation of specific biological targets.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 50k LinkedIn followers — 27.3% of this cohort's audience · 113 engagements/post (3.4× cohort median)
Funding rounds
- May 2024Post IPO$555.5M
- Jan 2018Grant (prize money)—
- Jun 2017Series B$51.4M
- Oct 2014Series B$32.2M
Founders & team
Investors
Gov, Deep Track Capital, EcoR1, Fairmount Funds Management, Forbion, Perceptive Advisors
Tech stack
Amazon Web ServicesCdnjsCloudflareDocusignDraftpress HfcmGoogle Analytics
#12
Series B · Cambridge, England · founded 2009 · 43 employees$141Mraised▾
Series B · Cambridge, England · founded 2009 · 43 employees
Biotechnology company developing antibody-based cancer immunotherapies and targeted biologic treatments. It uses advanced antibody engineering platforms to design highly targeted biologic medicines that harness the immune system to recognize and destroy cancer cells. Its pipeline includes innovative therapeutic antibodies and immune-oncology treatments aimed at improving efficacy, safety, and precision compared to traditional therapies.
Funding rounds
- Jul 2023Series B$32M
- Apr 2018Series B$70M
- Dec 2014Series B—
- Apr 2014Series A$3.3M
Founders & team
Investors
Sofinnova Partners, Andera Partners, Takeda, Quan Capital, Kreos Capital, BioNTech
Tech stack
WordpressMysqlPhpApache Http ServerStackpathHsts
Funding & investor landscape
$2.3Btotal disclosed funding
36companies funded
132disclosed rounds
0rounds last 90 days
Most active investors
Gov6 rounds
Notable founders
Azim Surani
Co-Founder · CellCentric
Will West
Co-Founder & CEO · CellCentric
Shweta Nair
Founder · Artios
Elena Seroff
Artist. Art Director. Curator. Founder · Artios
David Tuveson
Co-Founder · Mestag Therapeutics
Soumya Raychaudhuri
Co-Founder · Mestag Therapeutics
Haydn Prosser
Co-Founder & Director · T-Therapeutics
Allan Bradley
Co-Founder & CEO · T-Therapeutics
Evis Sala
Co-Founder · Lucida Medical
Antony Rix
Co-Founder & CEO · Lucida Medical
Jeroen Verheyen
Co-Founder & CEO · Semarion
Tarun Vemulkar
Co-Founder&CTO · Semarion
Prism market signals · United Kingdom · country-scoped Prism corpus, 1,711,828 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN CAMBRIDGE · Health & Bio
How research on Oncology in Cambridge is moving
A read on the academic research around Oncology in Cambridge — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 91 papers.
91 papers · stance +0.58 · 43% breakthrough · 11% concern
top institutions
- University of Cambridge59
- Cancer Research UK Cambridge Center32
- Cambridge University Hospitals NHS Foundation Trust19
- Cambridge School6
- Cambridge Hospital1
leading researchers
Christopher J. Ward · Jhuma Pramanik · Oliver Cast · Soura Chakraborty · Alex Watterson · Benjamin S. Beresford-Jones
prism intelligence · tone & topics
100% positive · 0% critical tone
BiotechnologyPharmaceuticalsMedical ResearchClinical TrialsHealthHealthcare
▲
Breakthroughs36 · 40%
▲ 25%→42% share
▲1.7× share momentum0 median citations92% since 2021mostly empirical
Breakthroughs are rising (25%→42% of field), led by Tumor microenvironment.
rising sub-themes (early→recent)
- Tumor microenvironment2→15
- Immune system1→9
- Cancer research2→8
- Cancer1→6
Newly emergingImmunotherapy 0→8 · Phenotype 0→6 · Transcriptome 0→5
Landmark Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells · 553 cites
◆
Advancements38 · 42%
▲ 25%→43% share
▲1.7× share momentum0 median citations89% since 2021mostly empirical
Advancements are rising (25%→43% of field), led by Cancer research.
rising sub-themes (early→recent)
- Cancer research2→12
- Immune system1→11
- Tumor microenvironment3→9
- Cancer1→4
Newly emergingImmunotherapy 0→13 · Pancreatic cancer 0→7 · Cancer immunotherapy 0→6
Landmark The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment · 1,195 cites
▼
Concerns9 · 10%
▼ 50%→6% share
▼0.1× share momentum31 median citations56% since 2021mostly reviews
Concerns are cooling (50%→6% of field), led by Tumor microenvironment.
rising sub-themes (early→recent)
- Tumor microenvironment7
- Cancer research3
- Stromal cell3
- Cancer2
- Context (archaeology)2
Landmark The Pancreas Cancer Microenvironment · 1,296 cites
Common questions
How many Oncology companies are there in Cambridge, United Kingdom?
Radar tracks 49 indexable Oncology companies headquartered in Cambridge, United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in Cambridge, United Kingdom?
The Oncology companies in Cambridge, United Kingdom on this list have raised a combined $2.3B in disclosed equity funding across 36 funded companies.
Which is the highest-funded Oncology company in Cambridge, United Kingdom?
Apollo Therapeutics is the highest-funded Oncology company in Cambridge, United Kingdom, with $371.5M in disclosed equity funding.
How many Oncology companies in Cambridge, United Kingdom are funded?
36 of the 49 Oncology companies in Cambridge, United Kingdom on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in Cambridge, United Kingdom?
None of the Oncology companies in Cambridge, United Kingdom on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Cambridge, United Kingdom Oncology companies?
The most active investors in Cambridge, United Kingdom Oncology companies on this list include University of Cambridge, Cambridge Innovation Capital, Gov, o2h ventures, SV Health Investors.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.